Novo Nordisk more than doubles 2025 obesity sales goal
Danish pharmaceutical firm Novo Nordisk has upgraded its sales predictions for its weight loss products after 78-percent growth in Q4.
by marketwire, translated by catherine brett
Novo Nordisk has more than doubled its goal for the sales of its obesity drugs, now aiming for over DKK 25bn (USD 3.7bn) in sales in 2025.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
